STAT3 and diabetes mellitus: Metformin use may reduce inflammation in patients with diabetes either through the improvement of metabolic disturbances such as hyperglycemia, insulin resistance and dyslipidemia or through its inhibition of the proinflammatory cancer-promoting nuclear factor κB and STAT3 pathways [38, 39].